CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Up 15.0% in January

CytoDyn Inc. (OTCMKTS:CYDY) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 20,123,400 shares, a growth of 15.0% from the December 31st total of 17,499,100 shares. Based on an average daily volume of 6,176,200 shares, the short-interest ratio is currently 3.3 days.

CytoDyn Price Performance

CytoDyn stock opened at $0.20 on Monday. The company’s 50-day moving average is $0.14 and its 200 day moving average is $0.14. CytoDyn has a 1-year low of $0.10 and a 1-year high of $0.32. The firm has a market capitalization of $243.09 million, a P/E ratio of -19.80 and a beta of -0.10.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.